Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.10), Zacks reports.
Lakewood-Amedex Biotherapeutics Stock Down 22.3%
LABT traded down $0.06 during midday trading on Monday, hitting $0.22. 828,332 shares of the company were exchanged, compared to its average volume of 7,485,027. The business has a 50 day moving average of $0.99. The stock has a market cap of $519,978.00 and a price-to-earnings ratio of -0.05. Lakewood-Amedex Biotherapeutics has a 1-year low of $0.17 and a 1-year high of $98.20.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on LABT shares. HC Wainwright started coverage on shares of Lakewood-Amedex Biotherapeutics in a research report on Wednesday, October 28th. They issued a “buy” rating on the stock. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Lakewood-Amedex Biotherapeutics presently has an average rating of “Hold”.
View Our Latest Research Report on Lakewood-Amedex Biotherapeutics
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Featured Articles
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
